FDA’s Dr. Ron Farkas, a fierce critic of Sarepta’s DMD drug, has joined Parexel

After days of rumors that Dr. Ron Farkas, a vocal FDA critic of Sarepta’s Duchenne med eteplirsen, had left the agency, Parexel has confirmed to FierceCRO that he has now in fact joined their company.

The FDA said on Wednesday that Farkas had left the regulator, and Parexel ($PRXL) confirmed to me on the same day that he joined the CRO “earlier this month,” and will be consulting as VP of integrated product development.

Dr. Farkas became known as a big critic of Sarepta’s recent attempt to get its DMD drug onto the market, saying it did not have great enough efficacy to warrant a green light.  

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

But he comes in at a tough time for Parexel, which recently lost its CFO, Ingo Bank, who quit over the summer just weeks before its Q4 results.

Several weeks ago, in a separate update, the CRO said it was delaying its mandated SEC performance report due to an “incident of misappropriation of corporate funds by an employee.”

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.